| Identification | Back Directory | [Name]
Ethanone, 2-(4-bromophenyl)-1-(2,4-dihydroxyphenyl)-, oxime, (1E)- | [CAS]
1239488-96-0 | [Synonyms]
URAT1&XO inhibitor 2
Ethanone, 2-(4-bromophenyl)-1-(2,4-dihydroxyphenyl)-, oxime, (1E)- | [Molecular Formula]
C14H12BrNO3 | [MOL File]
1239488-96-0.mol | [Molecular Weight]
322.15 |
| Chemical Properties | Back Directory | [Melting point ]
163-164 °C | [Boiling point ]
535.8±29.0 °C(Predicted) | [density ]
1.53±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
8.48±0.35(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia[1]. | [References]
[1] Hu Q, et al. (E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1. Biomed Pharmacother. 2017 Feb;86:88-94. DOI:10.1016/j.biopha.2016.12.002 |
|
|